China
· Delayed Price · Currency is CNY InnoCare Pharma Statistics
Total Valuation
InnoCare Pharma has a market cap or net worth of CNY 21.47 billion. The enterprise value is 16.11 billion.
| Market Cap | 21.47B |
| Enterprise Value | 16.11B |
Important Dates
The last earnings date was Wednesday, May 14, 2025.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 266.28M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -7.72% |
| Shares Change (QoQ) | +11.25% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.38B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.53 |
| PB Ratio | 3.17 |
| P/TBV Ratio | 3.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -57.48 |
| EV / Sales | 13.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -55.12 |
Financial Position
The company has a current ratio of 7.84, with a Debt / Equity ratio of 0.23.
| Current Ratio | 7.84 |
| Quick Ratio | 7.32 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | -5.29 |
| Interest Coverage | -9.56 |
Financial Efficiency
Return on equity (ROE) is -4.24% and return on invested capital (ROIC) is -3.19%.
| Return on Equity (ROE) | -4.24% |
| Return on Assets (ROA) | -2.63% |
| Return on Invested Capital (ROIC) | -3.19% |
| Return on Capital Employed (ROCE) | -4.79% |
| Revenue Per Employee | 1.12M |
| Profits Per Employee | -257,357 |
| Employee Count | 1,089 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 1.40 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +220.27% in the last 52 weeks. The beta is 0.96, so InnoCare Pharma's price volatility has been similar to the market average.
| Beta (5Y) | 0.96 |
| 52-Week Price Change | +220.27% |
| 50-Day Moving Average | 19.85 |
| 200-Day Moving Average | 14.53 |
| Relative Strength Index (RSI) | 66.14 |
| Average Volume (20 Days) | 6,454,672 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoCare Pharma had revenue of CNY 1.22 billion and -280.26 million in losses. Loss per share was -0.16.
| Revenue | 1.22B |
| Gross Profit | 1.07B |
| Operating Income | -402.87M |
| Pretax Income | -290.54M |
| Net Income | -280.26M |
| EBITDA | -334.06M |
| EBIT | -402.87M |
| Loss Per Share | -0.16 |
Balance Sheet
The company has 7.01 billion in cash and 1.54 billion in debt, giving a net cash position of 5.46 billion.
| Cash & Cash Equivalents | 7.01B |
| Total Debt | 1.54B |
| Net Cash | 5.46B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.77B |
| Book Value Per Share | 3.76 |
| Working Capital | 6.89B |
Cash Flow
In the last 12 months, operating cash flow was -224.98 million and capital expenditures -67.28 million, giving a free cash flow of -292.26 million.
| Operating Cash Flow | -224.98M |
| Capital Expenditures | -67.28M |
| Free Cash Flow | -292.26M |
| FCF Per Share | n/a |
Margins
Gross margin is 87.74%, with operating and profit margins of -32.89% and -22.88%.
| Gross Margin | 87.74% |
| Operating Margin | -32.89% |
| Pretax Margin | -23.72% |
| Profit Margin | -22.88% |
| EBITDA Margin | -27.27% |
| EBIT Margin | -32.89% |
| FCF Margin | n/a |
Dividends & Yields
InnoCare Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 7.72% |
| Shareholder Yield | n/a |
| Earnings Yield | -1.31% |
| FCF Yield | -1.36% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
InnoCare Pharma has an Altman Z-Score of 2.58. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.58 |
| Piotroski F-Score | n/a |